GEM-231

N/A

Report date: 2023/02/27 10:01:59
NME

Base Information

Drug NameGEM-231
Drug Alias NamePKAIAS-231GEM-231HYB-165HYB-0165
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActioncAMP-dependent protein kinase type I-alpha regulatory subunit inhibitors
TargetscAMP-dependent protein kinase type I-alpha regulatory subunit
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAceragen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIderaNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A